Panel Rejection Of Targanta’s Oritavancin Shows That MRSA Matters Most
Executive Summary
Unconvincing data in a subgroup of patients with methicillin-resistant Staphylococcus aureus was the deciding factor in an FDA panel's Nov. 19 vote against Targanta's oritavancin for complicated skin and skin structure infections
You may also be interested in...
Industry’s Lesson On Non-Inferiority Margins In Anti-Infective Trials: Use 10%
If industry is to learn anything from the three-day Anti-Infective Drugs Advisory Committee meeting on how to correctly use non-inferiority margins in trials, it is to adhere to the panel's recommendation of 10 percent (at least for now)
IFRA Hosts Capitol Hill Scent Experience In Timeout From Policy Concerns
The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.
NSF's Cosmetics Verification Program Fizzles, While EWG's Could See Second Boom
NSF International has put its cosmetic product verification program on ice due to lack of interest since its launch in April 2017. Meanwhile, more than 1,000 products from 75+ brands have earned the "EWG Verified" mark, and the NGO says interest is higher than ever following Walmart's announcement in September that it will begin pushing vendors to pursue the verification.